Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances

Matt MonacoAvatar
Written by Matt Monaco Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 11/30/2025, 8:05 am ET | 5 min
ImmunityBio Gains Momentum with Strong ANKTIVA Sales and Clinical Advances Thumbnail

In this article

  • IBRX-2.54%
    IBRX - NYSEImmunityBio Inc.
    $2.33-0.06 (-2.54%)
    Volume:  19.44M
    Float:  300.61M
    $2.28Day Low/High$2.46

ImmunityBio Inc.’s stocks have been trading up by 12.68 percent, driven by positive investor sentiment and impactful developments.

Healthcare industry expert:

Analyst sentiment – neutral

ImmunityBio, Inc. (IBRX) is in a precarious financial state despite a high gross margin of 99.6%. The company’s financial metrics reveal stark profitability challenges, with substantial deficits in EBIT, EBITDA, and pretax profit margins, indicating ongoing losses. Revenue stands at $14.74 million, but a price-to-sales ratio of 28.16 suggests overvaluation relative to sales. Financial health indicators like a current ratio of 5.8 show adequate liquidity, yet the negative book value per share and return metrics point to concerns over fiscal sustainability. Cash flow analysis highlights significant investment outflows, straining liquidity and necessitating strategic pivots.

Technically, ImmunityBio’s stock exhibits a mixed pattern, with recent fluctuations around key levels. The trading week highlighted includes a minor uptrend from a recent close of $2.05 to $2.4, signaling potential bullish sentiment. The breakout above $2.13 suggests near-term resilience, supported by moderate volume spikes. Despite this, a strategic approach would pivot around wait-and-see for continuity in upward momentum before entry. Traders should monitor critical support at $2.05 and resistance near $2.4, leveraging short-term oscillations as tactical cues.

Recent developments underscore ImmunityBio’s strategic expansion and market positioning, particularly with its drug ANKTIVA, leading to robust demand and clinical trial successes. The 467% growth year-to-date accentuates the therapeutic promise, reinforced by clinical trial advancements in severe cancer types. The alignment with consumer preference for immunotherapy over chemotherapy further bolsters the appeal and trajectory of ImmunityBio’s portfolio. While prevailing market indicators from broader sector benchmarks cast a shadow due to profitability woes, the growth vectors offer a compelling forward narrative. Immediate resistance exists around $2.40-$2.50, with a cautious outlook contingent on sustaining sales momentum and funding innovation.

  • ImmunityBio reports a 467% surge in unit growth year-to-date for 2025, marking $75 million in sales, driven by robust demand for ANKTIVA and promising results in diverse cancer treatments.

  • Third quarter EPS improved, surpassing consensus with ANKTIVA’s increased unit sales and recognition as a preferred drug by a major contracting organization, showing impressive clinical trial progress.

Candlestick Chart

Weekly Update Nov 24 – Nov 28, 2025: On Sunday, November 30, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 12.68%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ImmunityBio, a rising star in the biotechnology sector, continues to showcase financial resilience and strategic focus. With a remarkable 467% increase in 2025 year-to-date unit growth, the company reached $75 million in sales for its flagship product, ANKTIVA. This achievement underscores the product’s market potential, particularly highlighted in clinical successes across various cancer types, and lends weight to its expansion strategy. The company’s robust Q3 performance further demonstrated its capacity to beat earnings forecasts, notable in the earnings per share of (7c) which surpassed market expectations.

In terms of financial strength, the company’s current ratio stands at an impressive 5.8, reflecting strong liquidity. However, its profitability ratios reveal room for improvement, showing the growing pains typical of biotech firms pushing innovation. Gross margins at 99.6% provide some optimism amid negative EBIT and pre-tax profit margins. Meanwhile, the company’s valuation metrics indicate a challenging pricing environment, with enterprise value standing at $5.27 billion and price-to-sales ratio at 28.16, reflecting high market anticipation of future capabilities.

More Breaking News

IBRX stock has shown volatile trading patterns, with recent price movements witnessing an uptick from $2.13 to $2.4. This fluctuation represents investor reactions to the company’s ongoing developments and strategic announcements, setting a positive trajectory for ImmunityBio if such momentum sustains.

Conclusion

ImmunityBio is positioned for a pivotal role in revolutionizing cancer treatment through its advanced immunotherapy solutions. The company’s impressive sales growth and strategic clinical advancements reflect its potential to set new standards in the industry. However, to maintain its upward trajectory, ImmunityBio needs to preserve its focus on operational excellence, financial stewardship, and robust pipeline development. In the ever-dynamic landscape of the biotech market, it’s crucial for those involved in trading to follow sound principles. As millionaire penny stock trader and teacher Tim Sykes says, “Be patient, don’t force trades, and let the perfect setups come to you.” As trader confidence grows with the firm’s robust financial performance and strategic maneuvers, the potential for long-term value creation appears substantial. This outlook paves the way for ImmunityBio to capture significant market opportunity and redefine oncological care landscapes, reaffirming its status as a formidable entity in the biotechnology sector.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Matt Monaco

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
He is a diligent trader and teacher in his To The Moon Report blogs and Small Cap Rockets strategy webinars. He shows up every day, and expects his students to as well. Matt is fond of trading sketchy, volatile OTC stocks with profit potential. His favorite patterns are panic dip buys and breakouts.
Read More

In this article (YTD Performance)

  • IBRX-10.16%
    IBRX - NYSEImmunityBio Inc.
    $2.33-0.06 (-2.54%)
    Volume:  19.44M
    Float:  300.61M
    $2.28Day Low/High$2.46

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Learn The Formula That Has Created Over 50 Millionaires
TRADE LIKE TIM
notification icon
Subscribe to receive notifications